ID
46142
Beschreibung
Principal Investigator: Levi Garraway, Dana Farber Cancer Institute, Boston, MA, USA MeSH: Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000694 Translating whole exome sequencing (WES) for prospective clinical use may impact the care of cancer patients; however, multiple innovations are necessary for clinical implementation. These include: (1) rapid and robust WES from formalin-fixed paraffin embedded (FFPE) tumor tissue, (2) analytical output similar to data from frozen samples, and (3) clinical interpretation of WES data for prospective use. In this study, we describe a prospective clinical WES platform for archival FFPE tumor samples. The platform employs computational methods for effective clinical analysis and interpretation of WES data. When applied retrospectively to 511 exomes, the interpretative framework revealed a "long tail" of somatic alterations in clinically important genes. Prospective application of this approach identified clinically relevant alterations in 15/16 patients. Overall, this methodology may inform the widespread implementation of precision cancer medicine.
Link
Stichworte
Versionen (2)
- 14.12.22 14.12.22 - Simon Heim
- 29.01.25 29.01.25 - Akane Nishihara
Rechteinhaber
Levi Garraway, Dana Farber Cancer Institute, Boston, MA, USA
Hochgeladen am
29. Januar 2025
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
dbGaP phs000694 Clinical Cancer Sequencing
Subject ID and consent group of participants with tumors and involved in the "Clinical Cancer Sequencing" project.
- StudyEvent: dbGaP phs000694 Clinical Cancer Sequencing
- Subject ID and consent group of participants with tumors and involved in the "Clinical Cancer Sequencing" project.
- Subject ID, sample ID, and sample use of participants with tumors and involved in the "Clinical Cancer Sequencing" project.
- Subject ID and primary disease of participants with tumors and involved in the "Clinical Cancer Sequencing" project.
- Sample ID, sample type, and analyte type of participants with tumors and involved in the "Clinical Cancer Sequencing" project.
Ähnliche Modelle
Subject ID and consent group of participants with tumors and involved in the "Clinical Cancer Sequencing" project.
- StudyEvent: dbGaP phs000694 Clinical Cancer Sequencing
- Subject ID and consent group of participants with tumors and involved in the "Clinical Cancer Sequencing" project.
- Subject ID, sample ID, and sample use of participants with tumors and involved in the "Clinical Cancer Sequencing" project.
- Subject ID and primary disease of participants with tumors and involved in the "Clinical Cancer Sequencing" project.
- Sample ID, sample type, and analyte type of participants with tumors and involved in the "Clinical Cancer Sequencing" project.